Plain-English translation of NCT07130903 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two treatments for people with metastatic colorectal cancer—cancer that has spread to other parts of the body and no longer responds to standard chemotherapy. The study combines a new medication called with a special device that uses electromagnetic fields (TheraBionic P1). Researchers want to see if using both together can help people live longer and manage their cancer with acceptable side effects.
When colorectal cancer becomes advanced and stops responding to multiple standard treatments, patients have very few options left. This trial exists to find out whether this new combination approach—pairing a medication that targets specific pathways in cancer cells with an electromagnetic device—might give patients with this difficult-to-treat cancer a meaningful new choice.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would use the electromagnetic device (TheraBionic P1) three times daily at home, while also taking the medication by mouth daily—taking it for three weeks and then having one week off. You will have regular clinic visits for check-ups, blood tests, and imaging scans to see how you are responding and to monitor for any side effects. The trial is designed to involve about 102 patients total, and researchers will follow your progress over time to see if this combination helps you.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States